Cortex Announces Appointment of Dr. Matthew Lungren, Chief Data Science Officer for Microsoft Health & Life Sciences, to its Board of Directors
Cortex Announces Appointment of Dr. Matthew Lungren, Chief Data Science Officer for Microsoft Health & Life Sciences, to its Board of Directors
PR Newswire
MENLO PARK, Calif., May 15, 2024
Dr. Lungren brings expertise translating cutting-edge AI technology into valuable healthcare applications
MENLO PARK, Calif., May 15, 2024 /PRNewswire/ -- Cortex, a medical technology company aiming to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology, today announced the addition of clinical AI expert Dr. Matthew Lungren to its board of directors. Lungren is Chief Data Science Officer for Microsoft Health & Life Sciences where he focuses on translating cutting-edge technology, including AI and cloud services, into innovative healthcare applications.
"Dr. Lungren is a leader in his field, operating at the intersection of artificial intelligence and practically impactful healthcare applications," said Cortex CEO Duke Rohlen. "He brings a complementary set of experiences, capabilities and relationships to the board that will help us maximize the value of our Electrographic Flow mapping capability designed with AI."
As a physician and clinical machine learning researcher, Dr. Lungren maintains a part-time clinical practice at UCSF while also continuing collaborative research and teaching roles as an adjunct professor at Stanford University. Prior to joining Microsoft, he was a clinical interventional radiologist and research faculty at Stanford University Medical School, where he co-founded and led the Stanford Center for Artificial Intelligence in Medicine and Imaging (AIMI) and then Principal for Clinical AI and Machine Learning at Amazon Web Services in World Wide Public Sector Healthcare, focusing on business development for clinical machine learning technologies in the public cloud. His scientific work has led to more than 150 publications, and he has served as co-founder and advisor for early-stage startups as well as large fortune-500 companies on healthcare AI technology development and go-to-market strategy.
"Cortex aims to leverage the latest in what's possible with multimodal AI in medtech to drive new technologies and impact patient outcomes," said Lungren. "I look forward to contributing to the company's efforts to improve patient outcomes through providing clear, personalized insight into the underlying drivers of atrial fibrillation."
About Cortex
Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology. The OptiMap™ System is a 510(k) cleared, Electrographic Flow™ mapping solution designed with AI, enabling physicians to See What Matters.
About Ajax Health
Ajax Health is a turnkey growth solution for commercial-stage medtech companies. The Ajax team draws on decades of experience as entrepreneurs, operators, and investors and provides capital, capability, curated strategy, and creative deal structuring to create value for its strategic partners by accelerating product portfolio development. Ajax Health is headquartered in Menlo Park, CA with offices in New York City, Los Angeles, and Austin.
Media Contact: Will Kynes, wkynes@cortexep.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cortex-announces-appointment-of-dr-matthew-lungren-chief-data-science-officer-for-microsoft-health--life-sciences-to-its-board-of-directors-302146297.html
SOURCE Cortex
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now